Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Abbvie humira us loe date or loss of exclusivity january 2023?

See the DrugPatentWatch profile for humira

US loss of exclusivity (LOE) for Humira (adalimumab) occurred on January 31, 2023. This marked the end of AbbVie’s U.S. patent protection and allowed biosimilars to begin entering the U.S. market in 2023. If you’d like, I can list which biosimilars launched and when, or explain the difference between patent expiry and regulatory exclusivity.



Other Questions About Humira :

humira loe date Is there a generic version of humira available in the us yet? Dangers of humira? Does humira increase liver enzymes? Humira patent cliff? Humira adalimumab buy online? How does humira treat rheumatoid arthritis?